EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Intuitive Surgical, Inc. (ISRG) closed the most recent trading day at $422.90, moving -1.21% from the previous trading session. This move lagged the S&P 500's daily gain of 0.23%. On the other hand, the Dow registered a loss of 0.17%, and the technology-centric Nasdaq increased by 0.34%.Coming into today, shares of the company had gained 7.19% in the past month. In that same time, the Medical sector gained 2.69%, while the S&P 500 gained 3.96%.Investors will be eagerly watching for the performance of Intuit ...

Robotic-assisted surgery is a massive growth opportunity, and Intuitive Surgical looks to be in prime position to benefit from the potential.Nvidia (NASDAQ: NVDA) is the talk of the stock market these days. The artificial intelligence (AI) stock has hit a $3 trillion valuation and it looks unstoppable. But the danger in jumping aboard that bandwagon is that sooner or later, the excitement stops, and you may find out you bought shares near or at the peak.Investors have fallen into trouble with exciting growt ...

Loading...Loading...Intuitive Surgical, Inc. ISRG is well-poised for growth in the coming quarters, courtesy of its strength in robotics. The optimism, led by solid results in the last few quarters and its progress on the Artificial Intelligence front, is expected to contribute further. However, procedure adoption risks and stiff competition persist.Shares of this Zacks Rank #3 (Hold) company have risen 23.8% year to date compared with the industry's 6.6% growth. The S&P 500 Index has gained 12.4% during th ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Intuitive Surgical, Inc. (ISRG) .Intuitive Surgical currently has an average brokerage recommen ...

Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Intuitive Surgical Inc (ISRG) - Product Pipeline Analysis, 2024 Update" company profile has been added to ResearchAndMarkets.com's offering.This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive ...

Intuitive Surgical (ISRG) recently announced the FDA 510(k) clearance of a labeling revision for its da Vinci X and Xi specific to radical prostatectomy.This clearance was granted based on real-world evidence (RWE) gathered between 2007 and 2014, which shows that the overall five to 10-year survival rate after radical prostatectomy with robotic assistance is similar to that of non-robotic radical prostatectomy.Price PerformanceIn the past six months, ISRG shares have gained 34.7% compared with the industry’ ...

SUNNYVALE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the U.S. Food and Drug Administration (FDA) cleared a labeling revision for da Vinci X and Xi specific to radical prostatectomy. This clearance was based on real-world evidence (RWE) collected from 2007 to 2014 that demonstrates overall five- to 10-year survival following robotic-assisted radical prostatectomy is ...

The most recent trading session ended with Intuitive Surgical, Inc. (ISRG) standing at $403.39, reflecting a +1.25% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which registered a loss of 0.6% for the day. Elsewhere, the Dow saw a downswing of 0.86%, while the tech-heavy Nasdaq depreciated by 1.08%.Coming into today, shares of the company had gained 7.18% in the past month. In that same time, the Medical sector gained 1.32%, while the S&P 500 gained 3.15%.Analysts and inve ...

Industry Overview - The medical technology sector is gaining attention alongside biotechnology, with significant potential for improving patient outcomes [1] - The global medical device technology market was valued at $639.1 billion in 2021 and is projected to reach $953.4 billion by 2027, representing a compound annual growth rate (CAGR) of 7.1% [1] Company Analysis: Johnson & Johnson (JNJ) - Johnson & Johnson operates in both drug manufacturing and medical technology, providing solutions for heart rhythm disorders and neurovascular care [2] - Analysts rate JNJ as a moderate buy with an average price target of $175.21, with a high forecast of $215 per share [2] - In the trailing 12 months, JNJ reported net income of $17.07 billion on revenue of $85.68 billion, with projected earnings per share growth of 7.36% for fiscal 2024 [3] Company Analysis: Intuitive Surgical (ISRG) - Intuitive Surgical specializes in medical instruments and is known for its da Vinci Surgical System, enhancing minimally invasive care [5] - Analysts have a consensus strong buy rating for ISRG, with an average price target of $427.93 and an optimistic target of $475 per share [5] - The company achieved net income of $1.99 billion on sales of $7.32 billion in the trailing 12 months, with expected EPS growth of 10% for fiscal 2024 [6] Company Analysis: Stryker (SYK) - Stryker focuses on orthopedics and spinal business, providing implants for joint replacements and surgical equipment [7] - Analysts rate SYK as a strong buy with an average price target of $382.06, indicating about 14% upside potential [7] - In the trailing 12 months, Stryker reported net income of $3.36 billion on revenue of $20.96 billion, with projected EPS growth of 12.8% for fiscal 2024 [8]